After 9 months the tumor continued to be PET-CT negative and there were no noted side effects from the treatment.
Improving the outcomes that matter most — for your patients and your practice.
Read about the proven safety and efficacy of the CyberKnife® System for the treatment of trigeminal neuralgia.
Read about the safety and efficacy of CyberKnife SBRT for prostate cancer patients.
HEAD & NECK
Read about the superior clinical outcomes when treating head and neck cancer with helical TomoTherapy® over RapidArc.
CyberKnife monotherapy produced an early and stable reduction in PSA in a patient with low-risk organ-confined prostate cancer with minimal acute urinary toxicities and no
The CyberKnife is well-poised to improve the local control rates−this is accomplished with high doses per fraction delivered via a highly conformal approach; improvements in
The CyberKnife® System successfully reproduced an HDR-like dose distribution, delivering treatment in a minimally invasive fashion.
The patient was considered to be inoperable, and was referred by the neurosurgeon for radiosurgery using the CyberKnife® Robotic Radiosurgery System.
CyberKnife® treatments, with sub-millimeter accuracy and highly conformal dosimetry, was the only reasonable option to control the patient’s tumor without causing undue radiation-induced toxicity.
Six months after radiation treatments, the tumor was gone. The patient’s optic nerve and vision were spared, and the eyeball no longer protruded.
Using the TomoTherapy® Hi·Art® system’s precise dose guidance capabilities, the oncologist delivered intense radiation directly to the tumor during a week and a half of
Highly-homogeneous dose. Excellent bladder and rectal sparing. Excellent small bowel sparing.
Due to the tumor location, stereotactic radiosurgery (SRS) was indicated in favor of surgery. The patient proactively inquired six months prior regarding the possibility of